Sanctuary Advisors LLC Has $2.14 Million Holdings in GE HealthCare Technologies Inc. $GEHC

Key Points

• Sanctuary Advisors cut its stake by 80.5% in GE HealthCare in Q4, selling 107,763 shares and leaving 26,131 shares valued at about $2.14 million.
• Insiders are buying shares—including CFO James Saccaro and director Frank R. Jimenez—with insiders purchasing 9,229 shares (~$556,180) over the last three months, signaling management confidence.
• GE HealthCare trimmed FY26 EPS guidance to $4.80–$5.00

Sanctuary Advisors LLC cut its stake in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 80.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 26,131 shares of the company's stock after selling 107,763 shares during the period. Sanctuary Advisors LLC's holdings in GE HealthCare Technologies were worth $2,143,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in GEHC. Capital Research Global Investors grew its stake in shares of GE HealthCare Technologies by 25.0% during the third quarter. Capital Research Global Investors now owns 24,972,556 shares of the company's stock worth $1,875,400,000 after purchasing an additional 4,998,154 shares during the period. Dodge & Cox grew its stake in shares of GE HealthCare Technologies by 16.8% during the third quarter. Dodge & Cox now owns 27,517,311 shares of the company's stock worth $2,066,550,000 after purchasing an additional 3,949,361 shares during the period. Boston Partners acquired a new stake in shares of GE HealthCare Technologies during the third quarter worth $287,627,000. Temasek Holdings Private Ltd acquired a new stake in shares of GE HealthCare Technologies during the third quarter worth $99,922,000. Finally, Hotchkis & Wiley Capital Management LLC grew its stake in shares of GE HealthCare Technologies by 17.1% during the third quarter. Hotchkis & Wiley Capital Management LLC now owns 8,432,374 shares of the company's stock worth $633,271,000 after purchasing an additional 1,232,828 shares during the period. 82.06% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CFO James Saccaro purchased 3,310 shares of the business's stock in a transaction dated Friday, May 1st. The shares were bought at an average cost of $60.60 per share, for a total transaction of $200,586.00. Following the completion of the acquisition, the chief financial officer directly owned 87,471 shares in the company, valued at approximately $5,300,742.60. This trade represents a 3.93% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Frank R. Jimenez purchased 1,750 shares of the business's stock in a transaction dated Thursday, April 30th. The stock was purchased at an average price of $60.45 per share, for a total transaction of $105,787.50. Following the completion of the acquisition, the insider owned 93,932 shares of the company's stock, valued at approximately $5,678,189.40. This represents a 1.90% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have bought a total of 9,229 shares of company stock worth $556,180 over the last three months. Corporate insiders own 0.36% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on GEHC shares. JPMorgan Chase & Co. reduced their target price on GE HealthCare Technologies from $80.00 to $65.00 and set a "neutral" rating on the stock in a report on Thursday. Morgan Stanley lifted their target price on GE HealthCare Technologies from $80.00 to $85.00 and gave the stock an "equal weight" rating in a report on Wednesday, February 4th. The Goldman Sachs Group lowered GE HealthCare Technologies from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $81.00 to $65.00 in a report on Thursday. Barclays reduced their target price on GE HealthCare Technologies from $87.00 to $78.00 and set an "equal weight" rating on the stock in a report on Thursday. Finally, Piper Sandler reduced their target price on GE HealthCare Technologies from $96.00 to $88.00 and set an "overweight" rating on the stock in a report on Friday, April 17th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, GE HealthCare Technologies has a consensus rating of "Hold" and a consensus price target of $80.67.

GE HealthCare Technologies Stock Performance

Shares of GE HealthCare Technologies stock opened at $61.03 on Friday. The firm has a market cap of $27.76 billion, a price-to-earnings ratio of 14.60, a price-to-earnings-growth ratio of 1.39 and a beta of 0.75. The stock's 50-day moving average is $73.28 and its 200-day moving average is $77.56. GE HealthCare Technologies Inc. has a one year low of $58.75 and a one year high of $89.77. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.22 and a quick ratio of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The company reported $0.99 EPS for the quarter, missing analysts' consensus estimates of $1.07 by ($0.08). The firm had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.04 billion. GE HealthCare Technologies had a net margin of 9.10% and a return on equity of 20.46%. The business's revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.01 earnings per share. GE HealthCare Technologies has set its FY 2026 guidance at 4.800-5.000 EPS. Equities analysts predict that GE HealthCare Technologies Inc. will post 4.88 earnings per share for the current fiscal year.

GE HealthCare Technologies Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Friday, April 3rd will be issued a $0.035 dividend. This represents a $0.14 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Thursday, April 2nd. GE HealthCare Technologies's payout ratio is 3.35%.

Trending Headlines about GE HealthCare Technologies

Here are the key news stories impacting GE HealthCare Technologies this week:

• Positive Sentiment: Insiders are buying shares — CEO Peter Arduini, CFO James Saccaro and director Frank R. Jimenez increased positions (multiple Form 4 filings), which investors often interpret as management confidence in the company’s outlook. Read More. • Read More. • Read More.
• Positive Sentiment: Heavy call-option buying — an unusual surge in call volume suggests short-term bullish/speculative interest that can amplify upside moves. (No article link available)
• Neutral Sentiment: Wells Fargo lowered its price target to $75 but kept an overweight rating, signaling upside exists vs. current levels while tempering near-term expectations. Read More.
• Neutral Sentiment: Operational changes — GEHC announced a reorganization (Imaging + Advanced Visualization) and executive moves intended to improve execution; benefits could take multiple quarters to materialize. Read More.
• Negative Sentiment: Guidance cut and margin pressure — management trimmed FY26 EPS guidance to $4.80–5.00, citing inflation, higher component and freight costs and supply issues; this is the core reason for recent downside pressure. Read More.
• Negative Sentiment: Mixed Q1 results — revenue beat (~$5.13B) but EPS missed ($0.99 vs. $1.07 est.) and margins compressed, reinforcing short‑term risk to earnings. Read More.
• Negative Sentiment: Analyst downgrades / price‑target cuts — Citigroup, JPMorgan and others trimmed targets and ratings (e.g., PTs cut to ~$65–75), pulling sell‑side support lower and contributing to volatility. Read More.
• Negative Sentiment: Investor litigation inquiry — a Johnson Fistel investigation adds headline and legal risk that could increase volatility. Read More.

GE HealthCare Technologies Profile

GE HealthCare Technologies NASDAQ: GEHC is a global medical technology and diagnostics company that develops, manufactures and markets a broad range of products and services for healthcare providers. Its portfolio centers on diagnostic imaging systems, including MRI, CT, PET and X-ray modalities, as well as ultrasound equipment. The company also supplies patient monitoring and anesthesia delivery systems, interventional and surgical imaging solutions, and molecular imaging technologies used in both clinical care and research settings.

In addition to hardware, GE HealthCare offers software, analytics and lifecycle services aimed at improving clinical workflows and equipment uptime.

Want to see what other hedge funds are holding GEHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.